- Trials with a EudraCT protocol (1,152)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,152 result(s) found for: Placebo 40 or 80 mg.
Displaying page 18 of 58.
| EudraCT Number: 2013-004876-37 | Sponsor Protocol Number: PL37-C03-2013 | Start Date*: 2014-03-31 | |||||||||||
| Sponsor Name:Pharmaleads SA | |||||||||||||
| Full Title: A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pa... | |||||||||||||
| Medical condition: Neuropathic pain develops as a result of damage to, or dysfunction of, the system that normally signals pain. It may arise from a heterogeneous group of disorders that affect the peripheral and cen... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-000218-12 | Sponsor Protocol Number: C3421005 | Start Date*: 2019-08-23 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES ... | |||||||||||||
| Medical condition: TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-011736-35 | Sponsor Protocol Number: CHUBX 2009/02 | Start Date*: 2009-07-27 | |||||||||||
| Sponsor Name:CHU de Bordeaux | |||||||||||||
| Full Title: Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomisée versus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur les DYSkinésies induites par la L-Dopa... | |||||||||||||
| Medical condition: Maladie de Parkinson | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-005914-10 | Sponsor Protocol Number: CBA109389 | Start Date*: 2007-03-22 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: A Multicentre, Randomised, Double-blind, Placebo and Naproxen (500mg) BID controlled, Phase II Proof of Concept, Parallel Group Study to Assess the Efficacy and Safety of Oral GW842166 at Two Dose ... | |||||||||||||
| Medical condition: Osteoarthritis of the knee | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) ES (Completed) DK (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-002456-41 | Sponsor Protocol Number: 1218.15 | Start Date*: 2008-05-13 | |||||||||||
| Sponsor Name:Boehringer-Ingelheim Ellas AE | |||||||||||||
| Full Title: A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally onc... | |||||||||||||
| Medical condition: Patients with type 2 Diabetes Mellitus with insufficient glycaemic control. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) HU (Completed) PT (Completed) AT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000332-25 | Sponsor Protocol Number: version1 | Start Date*: 2012-06-19 |
| Sponsor Name:University of Birmingham | ||
| Full Title: vitamin D replacement to prevent lung injury following oesophagectomy - a randomised controlled trial. | ||
| Medical condition: perioperative inflammation in patients undergoing oesophagectomy. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-001590-24 | Sponsor Protocol Number: 01.01.18 | Start Date*: 2019-03-21 | |||||||||||
| Sponsor Name:University of Dundee [...] | |||||||||||||
| Full Title: A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis. | |||||||||||||
| Medical condition: Bronchiectasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Temporarily Halted) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-002627-32 | Sponsor Protocol Number: 2007-002627-32 | Start Date*: 2009-02-04 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg fingolimod administered orally once daily versus placebo in patients wit... | |||||||||||||
| Medical condition: Primary progressive multiple sclerosis. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) GB (Completed) FI (Completed) SE (Completed) ES (Completed) FR (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) HU (Completed) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003197-28 | Sponsor Protocol Number: CQBW251B2201 | Start Date*: 2019-08-02 | |||||||||||
| Sponsor Name:Novartis Pharma AG | |||||||||||||
| Full Title: A 24-week multi-center, double-blind, placebo controlled dose range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS) | |||||||||||||
| Medical condition: Chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) NL (Completed) BE (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) GR (Completed) HU (Completed) IT (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-020891-43 | Sponsor Protocol Number: D3320C00002 | Start Date*: 2010-10-07 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients with Moderate to ... | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003221-29 | Sponsor Protocol Number: XPF-008-201 | Start Date*: 2020-03-12 | |||||||||||
| Sponsor Name:Xenon Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Ex... | |||||||||||||
| Medical condition: Adult focal (partial onset) epilepsy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-004845-34 | Sponsor Protocol Number: ACT13480 | Start Date*: 2013-09-02 | |||||||||||
| Sponsor Name:Sanofi-aventis recherche et développement | |||||||||||||
| Full Title: A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients with Non-Infectious, Intermediate, Po... | |||||||||||||
| Medical condition: Uveitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000442-38 | Sponsor Protocol Number: TR02-109 | Start Date*: 2011-10-03 | |||||||||||
| Sponsor Name:Insmed Incorporated | |||||||||||||
| Full Title: Randomized, placebo-controlled, double-blind, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas Aer... | |||||||||||||
| Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002242-36 | Sponsor Protocol Number: GB001-2001 | Start Date*: 2018-12-06 | |||||||||||
| Sponsor Name:GB001, Inc. | |||||||||||||
| Full Title: A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to sev... | |||||||||||||
| Medical condition: Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Completed) GB (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000582-37 | Sponsor Protocol Number: CHOL00107 | Start Date*: 2007-09-21 | |||||||||||
| Sponsor Name:Genzyme Europe BV | |||||||||||||
| Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia | |||||||||||||
| Medical condition: Familial hypercholesterolaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002763-18 | Sponsor Protocol Number: HZNP-TEP-301 | Start Date*: 2018-02-22 | |||||||||||
| Sponsor Name:Horizon Therapeutics USA, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC Trial) | |||||||||||||
| Medical condition: Active Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-006637-19 | Sponsor Protocol Number: CARDIOL100-002 | Start Date*: 2022-12-01 | |||||||||||
| Sponsor Name:Cardiol Therapeutics Inc. | |||||||||||||
| Full Title: Impact of CardiolRxTM on Myocardial Recovery in Patients with Acute Myocarditis A double-blind, placebo-controlled trial (ARCHER) | |||||||||||||
| Medical condition: Acute Myocarditis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-013391-44 | Sponsor Protocol Number: EDX09/01 | Start Date*: 2010-02-05 | |||||||||||
| Sponsor Name:OM PHARMA SA | |||||||||||||
| Full Title: Multicentre, double blind, placebo-controlled, randomised clinical study to assess the efficacy and safety of Doxium® 500 three times daily in patients suffering from chronic venous insufficiency (... | |||||||||||||
| Medical condition: Chronic Venous Insufficiency (CVI) CEAP Class C3 or C4 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) PT (Completed) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003966-29 | Sponsor Protocol Number: BCX7353-302 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:BioCryst Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in... | |||||||||||||
| Medical condition: Hereditary angioedema | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Prematurely Ended) IE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) DK (Completed) HU (Completed) CZ (Completed) AT (Completed) NL (Ongoing) BE (Completed) ES (Completed) IT (Prematurely Ended) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004393-22 | Sponsor Protocol Number: LIB003-006 | Start Date*: 2022-01-13 | |||||||||||
| Sponsor Name:LIB Therapeutics, LLC | |||||||||||||
| Full Title: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disea... | |||||||||||||
| Medical condition: Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NO (Completed) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.